N/A N=100 Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion
Elevated Intracranial Pressure (ICP)
Primary: Changes in ONSD in mm With Changes in ICP in Healthy Volunteers. — 4.2 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=935 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Chronic Obstructive Pulmonary Disease
Primary: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period — 1.295; 0.859 Exacerbation per…
Phase 3 N=689 To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Adenocarcinoma of Lung
Primary: Objective Response Rate (ORR) During the Induction Study Period From Central Review — 42.40; 42.07 percentage of responders
Phase 2 N=38 AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
Advanced Solid Cancers · Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Primary: Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab — 0; 0; 0; 0 Participants
N/A N=10 Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)
Obesity · Morbid Obesity · Weight Loss
Primary: Change in Body Weight as Assessed by BMI (kg/m^2) — 43.7 kg/m^2
N/A N=133 Intervention to Promote Breast Cancer Screening Among American Indian Women
Breast Cancer
Primary: Number of Participants Who Received a Mammogram — 26; 12 Participants — p=.009
N/A N=107,317 Variations in Anesthesia Care for Hip Fracture Surgery
Hip Fractures · Anesthesia · Death
Primary: Number of Participants With All-Cause Mortality at 30-days — 9122 Participants
Phase 2 N=45 A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)
Advanced Solid Tumours
Primary: Monotherapy (Modules 1 and 2): Progression Free Survival Rate at 6 Months — NA; 6.1 percentage of participants
Phase 2 N=139 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Small Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors
Primary: Overall Survival — 6.85; 7.6; 7.5 Months
N/A N=178 The Effects of Executive Functions and Social Cognition on Mental Health
Autism or Autistic Traits · Mental Health Disorder · Executive Dysfunction
Primary: Depression_1 — 9.87; 10.24; 7.65; 9.15 score on a scale
Phase 2 N=205 A Study of LY3561774 in Participants With Mixed Dyslipidemia
Dyslipidemias · Lipid Metabolism Disorders · Metabolic Diseases
Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691
N/A N=706 Prediction of Recurrent Events With 18F-Fluoride
Coronary Artery Disease · Myocardial Infarction
Primary: Cardiac Death, Non-fatal Recurrent Myocardial Infarction or Unscheduled Coronary Revascularisation — 51; 90 Participants — p=0.20
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
N/A N=57 Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer
Neoplasms
Primary: Mean Changes From Baseline in Self-esteem Scores on the Rosenberg Self-esteem Scale (RSES) to Two-, Six-, and Eight Weeks Post Baseline — 23.4; 23.5; 23.7; 24.2 score on…
Phase 3 N=738 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR — 10.0; 8.1 Months — p=0.0002